ABBVIE ($ABBV) is expected to release its quarterly earnings data on Thursday, July 31st before market open, per Finnhub. Analysts are expecting revenue of $15,326,229,840 and earnings of $2.94 per share.
You can see Quiver Quantitative's $ABBV stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ABBVIE Insider Trading Activity
ABBVIE insiders have traded $ABBV stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- TIMOTHY J. RICHMOND (EVP, CHIEF HR OFFICER) has made 0 purchases and 6 sales selling 29,917 shares for an estimated $6,070,036.
- KEVIN K BUCKBEE (SVP, CONTROLLER) has made 0 purchases and 2 sales selling 18,944 shares for an estimated $3,853,372.
- SCOTT T REENTS (EVP, CHIEF FINANCIAL OFFICER) sold 17,644 shares for an estimated $3,746,526
- PERRY C SIATIS (EVP, GC AND SECRETARY) has made 0 purchases and 2 sales selling 5,778 shares for an estimated $1,143,452.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ABBVIE Hedge Fund Activity
We have seen 1,723 institutional investors add shares of ABBVIE stock to their portfolio, and 1,692 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GAMMA INVESTING LLC removed 10,182,211 shares (-99.5%) from their portfolio in Q2 2025, for an estimated $1,890,022,005
- CAPITAL INTERNATIONAL INVESTORS removed 7,996,758 shares (-28.0%) from their portfolio in Q1 2025, for an estimated $1,675,480,736
- FMR LLC added 5,539,207 shares (+30.6%) to their portfolio in Q1 2025, for an estimated $1,160,574,650
- BLACKROCK, INC. added 3,842,577 shares (+2.7%) to their portfolio in Q1 2025, for an estimated $805,096,733
- ASSENAGON ASSET MANAGEMENT S.A. added 3,666,521 shares (+550.9%) to their portfolio in Q2 2025, for an estimated $680,579,628
- GOLDMAN SACHS GROUP INC added 3,351,687 shares (+29.7%) to their portfolio in Q1 2025, for an estimated $702,245,460
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC added 3,134,454 shares (+inf%) to their portfolio in Q2 2025, for an estimated $581,817,351
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ABBVIE Government Contracts
We have seen $526,017 of award payments to $ABBV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- IMPLANTS: $36,934
- IMPLANT: $35,788
- 4567253744!NATRELLE TE SMOOTH 133S-SV-13-T: $33,629
- IMPLANTS: $29,604
- PROSTHETICS:SURGICAL IMPLANTS BREAST RECONSTRUCTION: $29,513
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
ABBVIE Congressional Stock Trading
Members of Congress have traded $ABBV stock 13 times in the past 6 months. Of those trades, 9 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 4 times. They made 3 purchases worth up to $45,000 on 05/22, 04/03, 04/01 and 1 sale worth up to $15,000 on 04/17.
- REPRESENTATIVE ROBERT BRESNAHAN has traded it 3 times. They made 2 purchases worth up to $30,000 on 05/15, 02/25 and 1 sale worth up to $15,000 on 04/08.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/05, 03/17 and 0 sales.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 2 times. They made 1 purchase worth up to $100,000 on 02/24 and 1 sale worth up to $100,000 on 04/17.
- REPRESENTATIVE JARED MOSKOWITZ purchased up to $15,000 on 04/07.
- REPRESENTATIVE DWIGHT EVANS sold up to $15,000 on 04/03.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ABBVIE Analyst Ratings
Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 04/29/2025
- Raymond James issued a "Outperform" rating on 04/28/2025
- Evercore ISI Group issued a "Outperform" rating on 04/28/2025
- Morgan Stanley issued a "Overweight" rating on 04/28/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/22/2025
- Wells Fargo issued a "Overweight" rating on 03/05/2025
- Truist Securities issued a "Buy" rating on 02/03/2025
To track analyst ratings and price targets for ABBVIE, check out Quiver Quantitative's $ABBV forecast page.
ABBVIE Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 12 analysts offer price targets for $ABBV in the last 6 months, with a median target of $215.5.
Here are some recent targets:
- Geoff Meacham from Citigroup set a target price of $205.0 on 05/14/2025
- Vamil Divan from Guggenheim set a target price of $216.0 on 04/29/2025
- Gary Nachman from Raymond James set a target price of $227.0 on 04/28/2025
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $205.0 on 04/28/2025
- Terence Flynn from Morgan Stanley set a target price of $250.0 on 04/28/2025
- Carter Gould from Cantor Fitzgerald set a target price of $210.0 on 04/22/2025
- Asad Haider from Goldman Sachs set a target price of $194.0 on 04/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
